Cargando…
MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
BACKGROUND: MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833215/ https://www.ncbi.nlm.nih.gov/pubmed/24129242 http://dx.doi.org/10.1038/bjc.2013.625 |
_version_ | 1782291808745684992 |
---|---|
author | Falkenberg, N Anastasov, N Rappl, K Braselmann, H Auer, G Walch, A Huber, M Höfig, I Schmitt, M Höfler, H Atkinson, M J Aubele, M |
author_facet | Falkenberg, N Anastasov, N Rappl, K Braselmann, H Auer, G Walch, A Huber, M Höfig, I Schmitt, M Höfler, H Atkinson, M J Aubele, M |
author_sort | Falkenberg, N |
collection | PubMed |
description | BACKGROUND: MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells. METHODS: MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT–PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222. RESULTS: In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed. CONCLUSION: This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy. |
format | Online Article Text |
id | pubmed-3833215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-38332152014-11-12 MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion Falkenberg, N Anastasov, N Rappl, K Braselmann, H Auer, G Walch, A Huber, M Höfig, I Schmitt, M Höfler, H Atkinson, M J Aubele, M Br J Cancer Molecular Diagnostics BACKGROUND: MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells. METHODS: MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT–PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222. RESULTS: In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed. CONCLUSION: This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy. Nature Publishing Group 2013-11-12 2013-10-15 /pmc/articles/PMC3833215/ /pubmed/24129242 http://dx.doi.org/10.1038/bjc.2013.625 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics Falkenberg, N Anastasov, N Rappl, K Braselmann, H Auer, G Walch, A Huber, M Höfig, I Schmitt, M Höfler, H Atkinson, M J Aubele, M MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
title | MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
title_full | MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
title_fullStr | MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
title_full_unstemmed | MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
title_short | MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
title_sort | mir-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833215/ https://www.ncbi.nlm.nih.gov/pubmed/24129242 http://dx.doi.org/10.1038/bjc.2013.625 |
work_keys_str_mv | AT falkenbergn mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT anastasovn mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT rapplk mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT braselmannh mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT auerg mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT walcha mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT huberm mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT hofigi mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT schmittm mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT hoflerh mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT atkinsonmj mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion AT aubelem mir221222differentiateprognosticgroupsinadvancedbreastcancersandinfluencecellinvasion |